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Abstract. Lung squamous cell carcinoma (SCC) is the second 
most common subtype of non-small cell lung carcinoma. 
The anticancer effects of arsenic trioxide (ATO) in lung 
adenocarcinoma and small-cell lung cancer have previously 
been reported; however its effects in SCC remain unclear. 
An MTT assay and western blot analysis were performed to 
determine cell viability and protein expression, respectively, in 
the SK-MES-1 and SW900 SCC cell lines following treatment 
with ATO. Phosphatidylserine externalization, mitochondrial 
membrane depolarization and cell cycle distribution were 
studied using flow cytometry and the in vivo effects of ATO on 
tumour growth were investigated with a xenograft model. The 
results demonstrated that SK-MES-1 and SW900 SCC cells 
were sensitive to clinically relevant concentrations of ATO. ATO 
induced apoptosis, mitochondrial membrane depolarization 
and G2/M arrest. In addition, treatment with ATO resulted 
in the downregulation of X-linked inhibitor of apoptosis, 
B-cell lymphoma-2 (Bcl-2), E2F transcription factor 1 (E2F1), 
thymidylate synthase and ribonucleotide reductase M1 in 
addition to the upregulation of Bcl-2 antagonist/killer protein, 
cleaved poly ADP-ribose polymerase and cleaved caspase 3 
in a cell‑line specific manner. In the SW900 xenograft model, 
tumour growth was inhibited by ATO with the formation of 
apoptotic bodies and downregulation of Bcl-2 and E2F1. In 
conclusion, ATO suppresses the growth of SCC in vitro and 
in vivo. 
Introduction
Lung cancer was responsible for the majority of cancer-asso-
ciated mortalities in China in 2014, with risk factors attributed 
to tobacco or asbestos exposure, indoor air pollution, carci-
nogenic products and genetic susceptibility (1). Lung cancer 
can be divided into non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC); 85% of cases are NSCLC (2). 
The major histological subtypes of NSCLC include adeno-
carcinoma, squamous cell carcinoma (SCC) and large cell 
carcinoma (3), with distinct phenotypes. SCC is the second 
most prevalent (~30%) among cases of NSCLC. Despite the 
recent advances of targeted therapy in lung adenocarcinoma, 
platinum doublet chemotherapy remains the cornerstone treat-
ment in metastatic SCC of the lung (4).
Arsenic trioxide (ATO) has previously been used as a 
traditional Chinese medicine; synergistic combination of ATO 
with all-trans retinoic acid (ATRA) has been demonstrated to 
lower the relapse rate during treatment of acute promyelocytic 
leukaemia (APL) (5). ATO activates the caspase signalling 
pathway, decreases the mitochondrial membrane potential and 
promotes the production of reaction oxygen species (ROS), 
leading to apoptosis (6). In addition, ATO induces apoptosis 
by downregulating B-cell lymphoma-2 (Bcl-2) and inducing 
G2/M cell cycle arrest (7).
The anticancer activity of ATO has been reported in other 
solid tumours (8). In addition, a previous study from our group 
reported the in vitro and in vivo activity of ATO in SCLC (9). 
Given the limited therapeutic options in advanced lung SCC, 
the aim of the present study was to investigate the role of ATO 
in treatment of SCC using in vitro cell line and in vivo tumour 
xenograft models.
Materials and methods
Cell lines and reagents. A panel of 4 squamous cell lung carci-
noma cell lines was obtained from American Type Culture 
Collection (Manassas, VA, USA). SK-MES-1 and SW900 cells 
were cultured in Eagle's Minimum Essential Medium (Gibco; 
Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 
Leibovitz's L‑15 medium (Gibco; Thermo Fisher Scientific, 
Inc.), respectively. H520 and H2170 cells were cultured in 
RMPI‑1640 medium (Gibco; Thermo Fisher Scientific, Inc.). 
All media were supplemented with 10% foetal bovine serum 
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(Gibco; Thermo Fisher Scientific, Inc.). Cells were incubated at 
37˚C in a humidified atmosphere supplied with 5% CO2. ATO 
(Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was 
dissolved in 1.65 M NaOH in a final concentration of 2.5 mM.
Cell viability assay. MTT assay was performed as previ-
ously described (10). SK-MES-1 (2,000 cells/well), SW900 
(20,000 cells/well), H520 (10,000 cells/well) or H2170 
(20,000 cells/well) cells were seeded in 96-well plate over-
night at 37˚C. Cells were incubated for 72 h with ATO solution 
(0.625, 1.25, 2.5, 5, 10 and 20 µM) and untreated cells served 
as a control. Cells were further incubated at 37˚C for 2 h 
following addition of 20 µl of MTT solution (0.25 mg/ml final 
concentration) (USB Corporation, Cleveland, OH, USA). All 
solutions were then removed and 50 µl dimethyl sulfoxide was 
added to solubilize the formazan crystals. Optical density was 
measured at 570 nm using a FLUOstar OPTIMA micro-plate 
reader (BMG Labtech GmbH, Ortenberg, Germany). All 
experiments were performed ≥3 times.
Annexin binding assay. Annexin binding assay was performed 
using an annexin V-phycoerythrin (PE)/7-aminoactinomycin 
D (7-AAD) apoptosis detection kit (BD Biosciences, 
Franklin Lakes, NJ, USA) (9). Cells were treated for 72 h 
with ATO (1.25, 2.5 and 5 µM) and untreated cells served 
as a control. Cells (1x106) were collected, washed with PBS 
and re-suspended in binding buffer. Cells were then stained 
for 15 min at room temperature in darkness with 300 µl 
binding buffer containing 5 µl of annexin V-PE and 5 µl of 
7-AAD. The excitation/emission (Ex/Em) of PE-annexin 
V and 7-AAD were 488/578 and 546/647 nm, respectively. 
Signals were detected using a flow cytometer (Cytomics 
FC500 with CXP software version 1.0, Beckman Coulter, 
Inc., Brea, CA, USA) using Fluorescence Light (FL), FL2 
and FL4 channels. A total of 10,000 events/sample were 
recorded. The percentage of apoptotic cells (PE+/7-AAD- 
and PE+/7-AAD+) was calculated. The experiments were 
performed in triplicate.
Mitochondrial membrane depolarization detection. JC-1 
(Sigma-Aldrich; Merck KGaA) staining was performed as 
previously described (11). Cells were treated for 72 h with 
ATO (1.25, 2.5 and 5 µM) and untreated cells served as a 
control. Cells (1x106) were collected, washed with PBS and 
stained at 37˚C for 15 min in darkness with JC‑1 (2 µM final 
concentration) in plain medium. Signals were detected using a 
flow cytometer (Cytomics FC500 with CXP software version 
1.0, Beckman Coulter, Inc.) with FL1 and FL2 channels. A 
total of 10,000 events/sample were captured. The experiments 
were performed in triplicate.
Cell cycle analysis.  Cells were treated for 72 h at the begin-
ning of experiment with ATO (1.25, 2.5 and 5 µM) and 
untreated cells served as a control. Cells were fixed with 70% 
cold ethanol and stored at ‑20˚C. Cells were incubated at 37˚C 
in the dark with plain medium containing RNase A (Thermo 
Fisher Scientific, Inc.) and propidium iodide (Sigma‑Aldrich). 
Signals were detected using a flow cytometer (Cytomics 
FC500 with CXP software version 1.0, Beckman Coulter, Inc.) 
with FL3 channel.
Western blot analysis. Western blot analysis was performed as 
previously reported (11). Cells (1x107) were collected and lysed 
for 1 h on ice with RIPA buffer (20 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% 
sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM 
β-glycerophosphate, 1 mM Na3VO4 and 1 µg/ml leupeptin) 
containing a protease inhibitor cocktail. Tissue samples were 
lysed for 1 h on ice with T-PER® Tissue Protein Extraction 
Reagent (Thermo Fisher Scientific, Inc.) containing a protease 
inhibitor cocktail. Protein concentration was detected using 
a Bradford assay (Bio-Rad Laboratories, Inc., Hercules, CA, 
USA). Protein (25-100 µg) was then mixed with a 5X sample 
buffer (0.1 M Tris-HCl, pH 6.8, 50% glycerol, 10% SDS, 
5% β-mercaptoethanol and 0.05% bromophenol blue) and 
boiled for 5 min. Proteins were separated using SDS-PAGE 
(10-15%). Proteins were then transferred to nitrocellulose 
blotting membranes (GE Healthcare Life Sciences, Little 
Chalfont, UK). The membrane was blocked at 4˚C for 1 h 
with 5% blotting-grade blocker (Bio-Rad Laboratories, Inc.) 
and further incubated at 4˚C overnight with primary antibody 
(Cell Signaling Technology, Inc., Danvers, MA, USA; all in 
1:1,000) [rabbit anti-human Bcl-2 antagonist/killer protein 
(Bak) (cat no. 3814), rabbit anti-human Bcl-2 (cat no. 2872), 
rabbit anti-human cleaved caspase 3 (cat no. 9661), rabbit 
anti-human E2F transcription factor 1 (E2F1; cat no. 3742), 
rabbit anti-human poly ADP-ribose polymerase (PARP; cat 
no. 9542), rabbit anti-human ribonucleotide reductase M1 
(RRM1; cat no. 8637), rabbit anti-human thymidylate synthase 
(TYMS; cat no. 5449) and rabbit anti-human X-linked 
inhibitor of apoptosis protein (XIAP; cat no. 2042)]. The 
membrane was washed at 4˚C for 10 min with Tris‑Buffered 
Saline and Tween 20 (TBST) 3 times. The membrane was then 
incubated at 4˚C for 90 min with corresponding horseradish 
peroxidase-conjugated secondary antibody (anti-mouse IgG, 
cat no. 7076, 1:1,000 or anti-rabbit IgG, cat no. 7074, 1:1,000; 
both from Cell Signaling Technology, Inc.). Protein expression 
was detected using Amersham™ ECL™ Western Blotting 
Detection Reagents (GE Healthcare Life Sciences, catalogue 
no. RPN2106). Relative protein expression was normalized 
with mouse anti-human β-actin (Sigma-Aldrich, cat no. A1978, 
1:1,000). Band intensities were analysed by GelQuant version 
1.8.2 (BioSystematica, Llandysul, UK).
Tumour growth inhibition in vivo. A total of 24 BALB/cA-nude 
mice (female, 4-6-week-old, 10-14 g, BALB/cAnN-nu, Charles 
River Laboratories, Wilmington, USA) were obtained and kept 
in 12/12 h light/dark cycle with temperature (16‑26˚C) and 
humidity (30-70%) control and ad libitum diet was provided. 
The animal protocol (approval reference number: 2860-12) was 
approved by the Animal Ethics Committee of The University 
of Hong Kong. SW900 cells (107) were re-suspended in 100 µl 
phosphate buffered saline and mixed with 100 µl ice-cold 
highly concentrated Matrigel matrix (BD Biosciences) prior 
to subcutaneous injection at the back of the nude mice. The 
mice were randomized into 3 groups (n=8) when the tumour 
volume reached 100 mm3. PBS and ATO (3.75 and 7.5 mg/kg) 
were injected intraperitoneally and daily in control and treat-
ment groups, respectively. Their general condition and body 
weight were monitored daily. Tumour size was measured on 
alternate days using digital calipers and calculated using the 
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formula [volume=1/2 x length x width x height] (12). The 
experimental endpoint was reached when the length of tumour 
exceeded 17 mm in the control group. Tumours were collected 
for western blot analysis and hematoxylin and eosin staining.
Hematoxylin and eosin staining. Tissues were fixed overnight 
at 4˚C in PBS 10% formaldehyde. Tissues were cut into 5 µm 
sections. The slides were deparaffinized by immersion in 
xylene (Merck KGaA). Subsequently, tissue sections were 
rehydrated with 100, 95 and 75% ethanol (Sigma-Aldrich; 
Merck KGaA) and distilled water (5 min for each step). Nuclei 
were stained for 2 min at room temperature with hematoxylin 
(Sigma-Aldrich; Merck KGaA) and cytoplasm was stained 
for 30 sec at room temperature with eosin (BD Biosciences) 
to visualize cellular structures. Slides were immersed in 
water to stop staining. For the dehydrating process, sections 
were dehydrated in 75, 95 and 100% ethanol and xylene 
(5 min for each step). Slides were mounted with Histofluid 
(Marienfeld-Superior, Germany). Images were captured using 
a Nikon Ni‑U fluorescence microscope (Nikon, Tokyo, Japan) 
equipped with a camera/detector Diagnostic Instrument RT3 
Slider (Meyer Instruments, Houston, USA). Pictures were 
captures at x200 magnification using CFI Plan Fluor DLL 20X 
objective (Nikon). Images were obtained using NIS-Elements 
Basic Research software (Laboratory Imaging, Prague, Czech 
Republic).
Statistical analysis. Data from three individual experiments 
are presented as the mean ± standard deviation. Comparison 
between groups was performed using Student's two-tailed 
t-test using Prism version 5.01 (GraphPad Software, Inc., La 
Jolla, CA, USA). P<0.05 was considered to indicate a statisti-
cally significant difference.
Results
ATO treatment decreases SK‑MES‑1 and SW900 cell viability. 
Cell viability was reduced by ATO in a dose-dependent manner 
in SK-MES-1 and SW900 cells (Fig. 1A). The half-maximal 
inhibitory concentration (IC50) values (72 h following ATO 
treatment) in SK-MES-1 and SW900 cells were 2.5 and 
5 µM, respectively, while those in H520 and H2170 cells 
were >10 µM. SK-MES-1 and SW900 cells were selected for 
further experiments, as their IC50 values were within clinically 
reachable concentrations of ATO (13). In SK-MES-1 cells, 
ATO treatment markedly increased the percentage of late 
apoptotic cells in a dose-dependent manner, as detected using 
an annexin V-PE/7-AAD assay. A concentration of 5 µM 
ATO significantly increased the percentage of late apoptotic 
cells compared with the control group (15 vs. 5%; P<0.05; 
Fig. 1B). In addition, treatment with 5 µM ATO significantly 
increased the percentage of SK-MES-1 cells with mitochon-
drial membrane depolarization compared with the control 
group (26 vs. 12%; P<0.05; Fig. 1C). Cell cycle analysis using 
propidium iodide staining demonstrated that ATO treatment 
induced G2/M arrest in SK-MES-1 and SW900 cells (Tables I 
and II).
Expression of apoptosis and DNA replication‑associated 
proteins following treatment with ATO. Following treatment 
with 5 µM ATO, expression of XIAP and Bcl‑2 was significantly 
downregulated in SW900 and SK-MES-1 cells, respectively, 
compared with the control groups (P<0.01 and P<0.05; Fig. 2A 
and B, respectively). Bak was significantly upregulated in 
SW900 cells compared with the control group (P<0.05; 
Fig. 2C) and expression of cleaved caspase 3 was significantly 
increased in SK-MES-1 and SW900 cells compared with the 
control groups (P<0.001 and P<0.05, respectively; Fig. 2D). A 
significant increase in cleaved PARP expression was observed 
in SK-MES-1 cells compared with the control group (P<0.01; 
Fig. 2E). ATO (1.25, 2.5 and 5 µM) treatment significantly 
downregulated the expression of E2F1 compared with the 
control group in SK-MES-1 (P<0.05, P<0.001 and P<0.001, 
respectively; Fig. 2F). RRM1 expression was significantly 
decreased compared with the control group in SK-MES-1 
cells (2.5 and 5 µM ATO; P<0.05 and P<0.01, respectively; 
Fig. 2G) and TYMS expression was significantly decreased in 
SK-MES-1 cells treated with 5 µM ATO compared with the 
control group (P<0.05; Fig. 2H).
In vivo effect of ATO in SW900 xenograft model. In order 
to assess the effect of ATO on tumour growth in vivo, mice 
were subcutaneously injected with SW900 cells, tumours were 
allowed to grow to ~100 mm3, then the mice were treated daily 
with PBS (control) or ATO (3.75 or 7.5 mg/kg). No signifi-
cant differences in baseline tumour volume were observed 
Table II. The percentage of cells in different phases of the cell 
cycle following ATO treatment in SW900 cells.
 Cell cycle phase distribution, %
 --------------------------------------------------------------------------------------
ATO dose Sub-G1 G1  S G2/M 
0 µM 3.1±1.5 56.8±1.9 10.4±1.7 29.7±1.3
1.25 µM 2.3±0.9 47.3±5.6 11.4±0.5 39.0±5.9
2.5 µM 2.3±0.6 44.0±1.8a 11.6±0.2 42.1±2.6a
5 µM 1.9±0.3 40.8±5.6b 11.3±1.2 46.0±5.4b
aP<0.01 and bP<0.001 compared with the control. ATO, arsenic 
trioxide.
Table I. The percentage of cells in different phases of the cell 
cycle following ATO treatment in SK-MES-1 cells.
 Cell cycle phase distribution, %
 --------------------------------------------------------------------------------------
ATO dose Sub-G1 G1 S G2/M
0 µM 9.9±4.6 55.1±4.0 14.2±2.1 20.9±2.8
1.25 µM 11.3±4.3 48.2±1.2a 16.6±3.6 23.9±2.0
2.5 µM 12.7±3.5 44.7±2.8a 15.5±5.6 27.1±0.9a
5 µM 10.6±5.3 36.4±1.1b 19.0±1.3 34.1±5.1a
aP<0.05 and bP<0.01 compared with the control. ATO, arsenic 
trioxide.
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between each group (Fig. 3A). The tumour size in control 
group of the SW900 xenograft model reached the humane 
endpoint on day 9, when mice were sacrificed and tumours 
were collected. Only high‑dose ATO (7.5 mg/kg) significantly 
suppressed tumour growth compared with the control group 
(P=0.0425; Fig. 3A). There were no evident toxic effects 
due to ATO treatment. Western blot analysis demonstrated 
significant downregulation of Bcl‑2 and E2F1 expression in 
tumour samples following 7.5 mg/kg ATO treatment (P<0.05; 
Fig. 3B). Hematoxylin and eosin staining revealed more apop-
totic bodies in the 7.5 mg/kg ATO group compared with the 
3.75 mg/kg and control groups (Fig. 3D).
Discussion
Data from the present study demonstrated that ATO 
significantly decreases the viability of the SK-MES-1 
and SW900 SCC cell lines within clinically achievable 
concentrations (13). ATO induced G2/M phase cell cycle 
arrest and activated apoptosis by upregulating a number of 
pro-apoptotic proteins. In addition, proteins associated with 
DNA replication and repair, including E2F1 and TYMS were 
downregulated following ATO treatment. Furthermore, ATO 
treatment significantly reduced tumour growth in vivo in a 
SW900 xenograft model.
ATO is a traditional Chinese medicine that has been used 
clinically as an anti-cancer agent in APL, with or without 
combined use of all-trans retinoic acid (14). ATO inhibits 
cell growth in solid tumours other than non-haematological 
carcinoma, including colorectal carcinoma (15). ATO induces 
apoptosis in lung adenocarcinoma (11) and SCLC in vitro 
and in vivo (9). However, the effect of ATO in SCC remains 
unknown.
Phosphatidylserine externalization is a recognition ligand 
for phagocytes to detect apoptotic cells (16). Phosphatidylserine 
externalization has been observed in H841 SCLC cells (9) and 
H23 lung adenocarcinoma cells (10). Mitochondrial membrane 
depolarization is another indicator of apoptosis; it has been 
demonstrated that ATO can induce mitochondrial membrane 
depolarization in lung cancer cells (11). DNA damage is 
typically sensed at the G1/S checkpoint or G2/M checkpoint, 
leading to either DNA repair or cell apoptosis. ATO treatment 
has been demonstrated to induce G2 arrest in Calu-6 cells 
(1-3 µM) (17).
Figure 1. ATO reduced cell viability, induced phosphatidylserine externalization and mitochondrial membrane depolarization in SK-MES-1 cells. 
(A) SK-MES-1 and SW900 cells were sensitive to ATO treatment with IC50 values of 2.5 and 5 µM respectively. H520 and H2170 cells were relative resistance 
to ATO. (B) ATO increased the percentage of cells undergoing apoptosis in SK-MES-1 cells in a dose-dependent manner. (C) ATO increased the proportion 
of cells undergoing mitochondrial membrane depolarization in SK-MES-1 cells in a dose-dependent manner. Results were measured in triplicate experiments. 
*P<0.05, compared with the control group. ATO, arsenic trioxide; IC50, half-maximal inhibitory concentration.
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XIAP belongs to the inhibitor of apoptosis protein family, 
and inhibits apoptosis through activation of the caspase 
activation pathway via caspase 3, 7 and 9 (18). A previous report 
demonstrated that expression of XIAP was decreased following 
Figure 2. Alteration of protein expression following ATO treatment. ATO induced (A) XIAP downregulation (SW900), (B) Bcl-2 suppression (SK-MES-1), 
(C) Bak upregulation (SW900), (D) CC3 elevation (SK-MES-1 and SW900), (E) cleaved PARP upregulation (SK-MES-1), (F) E2F1 suppression (SK-MES-1 
and SW900), (G) RRM1 downregulation (SK-MES-1) and (H) TYMS suppression (SK-MES-1). Results were measured in triplicate experiments. *P<0.05, 
**P<0.01 and ***P<0.001 compared with the control group. XIAP, X-linked inhibitor of apoptosis; Bcl-2, apoptosis regulator Bcl-2; Bak, Bcl-2 antagonist/killer 
protein; CC3, cleaved caspase 3; PARP, poly ADP-ribose polymerase; RRM1, ribonucleotide reductase M1; TYMS, thymidylate synthase.
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ATO treatment in SCLC H841 cells (9). Bcl-2 is responsible 
for the release of apoptotic inducing factor and cytochrome 
c from the mitochondria, which leads to apoptosis (19). Bcl-2 
has been revealed to be downregulated following ATO treat-
ment in lung adenocarcinoma (11) and SCLC (9). Bak is a 
pro-apoptotic member of the Bcl-2 family of proteins (20) and 
has been demonstrated to be upregulated in ATO-treated lung 
adenocarcinoma cell lines, an effect mediated by truncation of 
BH3-interacting domain death agonist (11).
PARP is a nuclear protein that facilitates DNA repair 
when cells are undergoing genomic DNA damage from envi-
ronmental stress (21). PARP is one of the major substrates 
for executor caspase 3, which represents a hallmark of 
apoptosis (22). Activation of caspase 3 was observed in lung 
adenocarcinoma (23) and SCLC (9).  Caspase-dependent 
apoptosis can be divided into the intrinsic (mitochon-
dria-mediated) and extrinsic (death receptor-mediated) 
pathways (24). Data from the present study demonstrated that 
in ATO-treated SK-MES-1 cells, downregulation of Bcl-2 was 
accompanied by mitochondrial membrane depolarization. 
Cleavage of caspase-3 and an increase in PARP expression 
indicated that the intrinsic pathway was activated by ATO in 
SK-MES-1 cells. By contrast, in ATO-treated SW900 cells, 
upregulation of Bak did not induce mitochondrial membrane 
depolarization. Suppression of XIAP and activation of 
caspase-3 suggested that the extrinsic pathway could be the 
predominant pathway in this cell type. Therefore, ATO could 
induce apoptosis via different pathways that were cell-line 
dependent.
E2F1 is a transcription factor belonging to the E2F family 
of proteins, which is involved in the G1 to S phase transition 
and cancer cell proliferation (25). High E2F1 gene expression 
in NSCLC has been associated with more aggressive pheno-
type of tumour cells (25). In addition, ATO has previously 
been demonstrated to downregulate E2F1 and its associated 
genes, including cyclin A2, c-myc and S-phase kinase associ-
ated protein 2 in lung adenocarcinoma (11).
TYMS is a key enzyme for the biosynthesis of thymi-
dylate and is involved in DNA synthesis (26). High tumoral 
TYMS expression has been associated with poor clinical 
outcomes (25). In addition, ATO has been demonstrated to 
downregulate TYMS protein and mRNA expression, leading 
to tumour growth inhibition in lung adenocarcinoma cell 
lines (11).
RRM1 encodes the regulatory subunit of ribonucleotide 
reductase and acts on ribonucleoside diphosphates that are 
required for deoxynucleotide production (27). A previous 
clinical study demonstrated that patients with higher tumoral 
RRM1 expression exhibited a lower survival rate when treated 
with gemcitabine-based therapy (28). ATO downregulated 
Figure 3. ATO suppressed squamous cell lung carcinoma tumour growth in vivo. (A) ATO (7.5 mg/kg) suppressed tumour growth in SW900 xenograft 
compared with the control group. (B) The expression of Bcl-2 and E2F1 was downregulated in the 7.5 mg/kg ATO treatment group compared with the control 
group. (C) Detection of apoptotic bodies (indicated by arrows) in ATO treatment groups using hematoxylin and eosin staining. *P<0.05, **P<0.01 compared 
with the control.
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RRM1 expression in lung adenocarcinoma, which may cause 
inhibition of DNA synthesis (11).
In conclusion, the results from the present study indicate 
that ATO decreases the viability of SCC SK-MES-1 and 
SW900 cells within clinically achievable concentrations, 
partially through apoptosis and inhibition of cell proliferation. 
Furthermore, ATO induced apoptosis via the intrinsic pathway 
in SK-MES-1 cells and the extrinsic pathway in SW900 cells. 
The antitumor effects of ATO were confirmed using a xeno-
graft model.
References
 1. Hu J, Qian GS and Bai CX: Lung Cancer Study Group of 
Chinese Thoracic S and Chinese Alliance Against Lung 
Cancer Expert Group: Chinese consensus on early diagnosis 
of primary lung cancer (2014 version). Cancer 121 (Suppl 17): 
S3157-S3164, 2015.
 2. Ho JC, Tam TC and Lam SK: Salvage therapy beyond targeted 
therapy in lung adenocarcinoma. Semin Respir Crit Care Med 34: 
837-844, 2013.
 3. West H, Harpole D and Travis W: Histologic considerations for 
individualized systemic therapy approaches for the management 
of non-small cell lung cancer. Chest 136: 1112-1118, 2009.
 4. Ang YL, Tan HL and Soo RA: Best practice in the treatment 
of advanced squamous cell lung cancer. Ther Adv Respir Dis 9: 
224-235, 2015.
 5. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, 
Pierce S, Blamble D, Estrov Z, Wierda W, et al: Effective treat-
ment of acute promyelocytic leukemia with all-trans-retinoic 
acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin 
Oncol 27: 504-510, 2009.
 6. Rojewski MT, Körper S and Schrezenmeier H: Arsenic trioxide 
therapy in acute promyelocytic leukemia and beyond: From 
bench to bedside. Leuk Lymphoma 45: 2387-2401, 2004.
 7. Park JW, Choi YJ, Jang MA, Baek SH, Lim JH, Passaniti T and 
Kwon TK: Arsenic trioxide induces G2/M growth arrest and 
apoptosis after caspase-3 activation and bcl-2 phosphorylation in 
promonocytic U937 cells. Biochem Biophys Res Commun 286: 
726-734, 2001.
 8. Evens AM, Tallman MS and Gartenhaus RB: The potential 
of arsenic trioxide in the treatment of malignant disease: Past, 
present, and future. Leuk Res 28: 891-900, 2004.
 9. Zheng CY, Lam SK, Li YY and Ho JC: Arsenic trioxide-induced 
cytotoxicity in small cell lung cancer via altered redox homeostasis 
and mitochondrial integrity. Int J Oncol 46: 1067-1078, 2015. 
10. Lam SK, Mak JC, Zheng CY, Li YY, Kwong YL and Ho JC: 
Downregulation of thymidylate synthase with arsenic trioxide in 
lung adenocarcinoma. Int J Oncol 44: 2093-2102, 2014. 
11. Lam SK, Li YY, Zheng CY, Leung LL and Ho JC: E2F1 down-
regulation by arsenic trioxide in lung adenocarcinoma. Int J 
Oncol 45: 2033-2043, 2014. 
12. Euhus DM, Hudd C, LaRegina MC and Johnson FE: Tumor 
measurement in the nude mouse. J Surg Oncol 31: 229-234, 1986.
13. Ardalan B, Subbarayan PR, Ramos Y, Gonzalez M, Fernandez A, 
Mezentsev D, Reis I, Duncan R, Podolsky L, Lee K, et al: A 
phase I study of 5‑fluorouracil/leucovorin and arsenic trioxide 
for patients with refractory/relapsed colorectal carcinoma. Clin 
Cancer Res 16: 3019-3027, 2010.
14. Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, Lau JS 
and Kwong YL: Oral arsenic trioxide-based maintenance regimens 
for first complete remission of acute promyelocytic leukemia: A 
10-year follow-up study. Blood 118: 6535-6543, 2011.
15. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, 
Ohishi N and Yagi K: Arsenic trioxide-induced apoptosis 
through oxidative stress in cells of colon cancer cell lines. Life 
Sci 70: 2253-2269, 2002.
16. Elmore S: Apoptosis: A review of programmed cell death. 
Toxicol Pathol 35: 495-516, 2007.
17. Han YH, Kim SZ, Kim SH and Park WH: Arsenic trioxide 
inhibits the growth of Calu-6 cells via inducing a G2 arrest of the 
cell cycle and apoptosis accompanied with the depletion of GSH. 
Cancer Lett 270: 40-55, 2008.
18. Silke J, Kratina T, Ekert PG, Pakusch M and Vaux DL: Unlike 
Diablo/smac, Grim promotes global ubiquitination and specific 
degradation of X chromosome-linked inhibitor of apoptosis 
(XIAP) and neither cause apoptosis. J Biol Chem 279: 4313-4321, 
2004.
19. Seite P, Hillion J, d'Agay MF, Gaulard P, Cazals D, Badoux F, 
Berger R and Larsen CJ: BCL2 gene activation and protein 
expression in follicular lymphoma: A report on 64 cases. 
Leukemia 7: 410-417, 1993. 
20. Chao DT and Korsmeyer SJ: BCL-2 family: Regulators of cell 
death. Annu Rev Immunol 16: 395-419, 1998.
21. Satoh MS and Lindahl T: Role of poly (ADP-ribose) formation in 
DNA repair. Nature 356: 356-358, 1992.
22. Han YH, Kim SZ, Kim SH and Park WH: Arsenic trioxide 
inhibits growth of As4.1 juxtaglomerular cells via cell cycle 
arrest and caspase-independent apoptosis. Am J Physiol Renal 
Physiol 293: F511-F520, 2007.
23. Kim HR, Kim EJ, Yang SH, Jeong ET, Park C, Kim SJ, Youn MJ, 
So HS and Park R: Combination treatment with arsenic trioxide 
and sulindac augments their apoptotic potential in lung cancer 
cells through activation of caspase cascade and mitochondrial 
dysfunction. Int J Oncol 28: 1401-1408, 2006. 
24. Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis 
pathways in cancer therapy. CA Cancer J Clin 55: 178-194, 2005.
25. Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K 
and Wada H: E2F1 overexpression correlates with thymidylate 
synthase and survivin gene expressions and tumor proliferation 
in non small-cell lung cancer. Clin Cancer Res 13: 6938-6946, 
2007.
26. Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H 
and Seeber S: Thymidylate synthase inhibitors in cancer therapy: 
Direct and indirect inhibitors. J Clin Oncol 15: 389-400, 1997.
27. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, 
Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, 
Staphopoulos E, et al: Tumor BRCA1, RRM1 and RRM2 mRNA 
expression levels and clinical response to first‑line gemcitabine 
plus docetaxel in non-small-cell lung cancer patients. PLoS 
One 3: e3695, 2008.
28. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, 
Camps C, Provencio M, Isla D, Taron M, Diz P, et al: 
Ribonucleotide reductase messenger RNA expression and 
survival in gemcitabine/cisplatin-treated advanced non-small 
cell lung cancer patients. Clin Cancer Res 10: 1318-1325, 
2004.
